+ Watch OXBT
on My Watchlist
Oxygen Biotherapeutics is a very fascinating name. At least I think so. That's why I got into researching it. Thing is, though, it's got so many competitors it ain't even funny. All of them seemed at least equally capable, if not more capable. So I think it's safe to say that OXBT is going to go down because it's in a rough world, and it doesn't have the capability to rise to the top. In addition, its sales have gone down this year. Losing demand in its products, and giving them to its capable competitors is not exactly the formula for rising stock price.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions